Yilkal Tariku Belay, The Advantages of Employing the Immune Response Mediated by Immunoglobulins in Preclinical and Clinical Research: An Essential Review, Journal of Advanced Therapeutic Science, Volume 1, Issue 2, 2026, Pages 01-15, ISSN Coming Soon, https://doi.org/.
(https://jphi-healthcarejournals.net/advanced-therapeutic-science/article/the-advantages-of-employing-the-immune-response-mediated-by-immunoglobulins-in-preclinical-and-clinical-research-an-essential-review-2394)
Abstract: Immunoglobulins, commonly known as antibodies, are glycoprotein molecules present on B lymphocytes and within the bloodstream. They are essential components of the immune response, as they detect the harmful molecules of test compounds and stimulate the immune system to manifest proportional counter-responses. This means that when the body encounters harmful molecules and pathogens, B cells must respond to every harmful antigen by producing antibodies tailored to bind to those antigens. This process is enhanced through class switching, which allows B cells to change the type of antibody they produce, and somatic hyper-mutation, which increases the binding affinity of antibodies by introducing mutations in the antibody genes. These mechanisms ensure an effective and precise immune response, enabling the body to defend itself efficiently against a wide range of harmful antigens and adapt its response to future infections or chemical exposures. First, to effectively evaluate the variations in the production of immunoglobulins, it is essential to conduct a thorough Immunoassay before administering any test compound to a study animal. This preliminary assessment not only establishes a crucial baseline for immunoglobulin levels that helps researchers assess the health status of a study animal but also sets the stage for an insightful analysis of subsequent changes. Following the dosing of the test compound, a follow-up Immunoassay becomes necessary to monitor any fluctuations in immunoglobulin levels over time. Careful analysis of these fluctuations is vital for understanding the interaction between harmful molecules and drug receptors, as well as for determining the rates and severity of toxic reactions resulting from the test compound using computational systems pharmacology. By adopting this comprehensive strategy, researchers can delve deeper into evaluating the therapeutic efficacy and safety profiles of potential agents, thereby enhancing our overall understanding of their effects on study subjects. This approach ultimately contributes to informed decision-making in the development of new and effective treatments. This proactive approach not only enhances the overall reliability and reproducibility of research findings but also aligns with ethical standards regarding animal welfare in scientific investigations. By rigorously ensuring that only healthy animals are included in trials, researchers promote humane treatment and foster a more responsible use of animal models in the pursuit of scientific knowledge. Above all, this approach avoids potential animal sacrifice for a toxicity study. This commitment to ethical clinical practices ultimately contributes to the advancement of medical research while safeguarding the welfare of laboratory animals.
Keywords: Immunoglobulins; Preclinical trial; Clinical trial; Toxic severity; Toxic reaction rate